IDXG: AI 评分 51/100 — AI 分析 (4月 2026)

Interpace Biosciences, Inc. specializes in molecular diagnostic tests and pathology services, focusing on cancer risk assessment. Their suite of diagnostic solutions aids physicians in the early detection and management of various cancers.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Interpace Biosciences, Inc. delivers molecular diagnostic solutions for cancer risk assessment, leveraging its PathFinderTG platform. Its key differentiators include PancraGEN and ThyGeNEXT tests, serving physicians and hospitals in the U.S. healthcare sector with a focus on early cancer detection and personalized medicine.

IDXG是做什么的？

Interpace Biosciences, Inc., founded in 1986 and headquartered in Parsippany, New Jersey, provides molecular diagnostic tests, bioinformatics, and pathology services focused on evaluating cancer risk. Originally incorporated as Interpace Diagnostics Group, Inc., the company rebranded in November 2019 to Interpace Biosciences, Inc., reflecting its enhanced focus on innovative bioscience solutions. Interpace's core offerings include PancraGEN, a genomic test designed for pancreatic cysts and pancreaticobiliary solid lesions, aiding physicians in assessing the risk of pancreaticobiliary cancers. This test utilizes the company's proprietary PathFinderTG platform. PanDNA, a molecular-only version of PancraGEN, offers a snapshot of key diagnostic factors. ThyGeNEXT is another key product, an oncogenic mutation panel used to identify malignant thyroid nodules. Additionally, ThyraMIR assesses thyroid nodules for malignancy risk using a microRNA gene-expression assay. RespriDx is a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. Interpace also provides pharmacogenomics testing, genotyping, biorepository, and customized services to pharmaceutical and biotech companies, serving physicians, hospitals, and clinics across the United States.

IDXG的投资论点是什么？

Interpace Biosciences, Inc. presents a focused investment opportunity within the molecular diagnostics sector. With a market capitalization of $0.01 billion and a P/E ratio of 1.56, the company demonstrates potential value. A gross margin of 64.6% indicates efficient operations. Key growth catalysts include the expansion of its PancraGEN and ThyGeNEXT testing services. The company's ability to leverage its PathFinderTG platform for new diagnostic applications is a significant value driver. Potential risks include competition from larger diagnostic firms and the need for continuous innovation to maintain market relevance. Investors should monitor the company's ability to expand its customer base and secure favorable reimbursement policies for its tests.

IDXG在哪个行业运营？

Interpace Biosciences, Inc. operates in the rapidly evolving medical diagnostics and research industry. The market is driven by increasing demand for personalized medicine and early cancer detection. Competitive landscape includes companies offering similar molecular diagnostic tests, such as AVCRF, CPIVF, ICBU, LIFD, and RMSL. The industry is characterized by continuous innovation and regulatory scrutiny. Interpace's focus on pancreatic and thyroid cancer diagnostics positions it within a niche market with specific clinical needs.

Medical - Diagnostics & Research

Healthcare

IDXG有哪些增长机遇？

Expansion of PancraGEN Testing: Interpace Biosciences can expand the market penetration of its PancraGEN test for pancreatic cyst and pancreaticobiliary lesion risk assessment. The market for pancreatic cancer diagnostics is projected to grow as early detection improves patient outcomes. By increasing awareness and adoption of PancraGEN among gastroenterologists and oncologists, Interpace can drive revenue growth. Timeline: Ongoing.
Increased Adoption of ThyGeNEXT: The ThyGeNEXT oncogenic mutation panel for thyroid nodules represents a significant growth opportunity. As guidelines for thyroid nodule management evolve, molecular testing is becoming increasingly important. Interpace can focus on educating endocrinologists and surgeons about the benefits of ThyGeNEXT in improving diagnostic accuracy and reducing unnecessary surgeries. Timeline: Ongoing.
Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Interpace with a steady stream of patient samples and enhance its market reach. By integrating its diagnostic tests into clinical workflows, Interpace can streamline the testing process and improve turnaround times. These partnerships can also facilitate the collection of valuable clinical data for research and development purposes. Timeline: Ongoing.
Development of New Diagnostic Assays: Interpace can leverage its PathFinderTG platform to develop new diagnostic assays for other types of cancer. By expanding its test menu, Interpace can address a broader range of clinical needs and diversify its revenue streams. Focus areas could include liquid biopsies for early cancer detection and companion diagnostics for targeted therapies. Timeline: 2027-2028.
Geographic Expansion: While currently focused on the United States, Interpace Biosciences can explore opportunities to expand its geographic reach into international markets. The demand for molecular diagnostic tests is growing globally, particularly in countries with advanced healthcare systems. By partnering with distributors and establishing local laboratories, Interpace can tap into new markets and accelerate its growth. Timeline: 2028-2030.

Market Cap of $0.01B, indicating a small-cap company with potential for growth.
P/E Ratio of 1.56, suggesting the company may be undervalued compared to its earnings.
Gross Margin of 64.6%, reflecting efficient cost management in its diagnostic testing services.
Profit Margin of 11.5%, demonstrating the company's ability to generate profit from its revenue.
Beta of 1.02, indicating the stock's volatility is similar to the overall market.

IDXG提供哪些产品和服务？

Provides molecular diagnostic tests for evaluating cancer risk.
Offers PancraGEN for pancreatic cyst and pancreaticobiliary lesion genomic testing.
Provides PanDNA, a molecular-only version of PancraGEN.
Offers ThyGeNEXT, an oncogenic mutation panel for thyroid nodules.
Provides ThyraMIR for assessing thyroid nodules for malignancy risk.
Offers RespriDx, a genomic test for differentiating metastatic or recurrent lung cancer.
Provides pharmacogenomics testing and genotyping services.
Offers biorepository and customized services to pharmaceutical and biotech industries.

IDXG如何赚钱？

Directly sells molecular diagnostic tests to physicians, hospitals, and clinics.
Generates revenue through test reimbursement from insurance companies and government payers.
Offers customized services to pharmaceutical and biotech companies on a contract basis.
Leverages its PathFinderTG platform to develop and commercialize new diagnostic assays.

Physicians specializing in gastroenterology, oncology, and endocrinology.
Hospitals and clinics offering diagnostic testing services.
Pharmaceutical and biotech companies requiring pharmacogenomics and genotyping services.
Patients seeking early cancer detection and personalized treatment options.

Proprietary PathFinderTG platform enables the development of novel diagnostic assays.
Established relationships with physicians and hospitals in the United States.
Strong focus on pancreatic and thyroid cancer diagnostics.
Expertise in molecular diagnostics and bioinformatics.

什么因素可能推动IDXG股价上涨？

Ongoing: Expansion of PancraGEN testing services for pancreatic cancer risk assessment.
Ongoing: Increased adoption of ThyGeNEXT oncogenic mutation panel for thyroid nodules.
Upcoming: Potential partnerships with hospitals and clinics to integrate diagnostic tests into clinical workflows.
Upcoming: Development of new diagnostic assays for other types of cancer leveraging the PathFinderTG platform.
Ongoing: Geographic expansion into international markets to tap into growing demand for molecular diagnostic tests.

IDXG的主要风险是什么？

Potential: Changes in reimbursement policies impacting revenue from diagnostic testing services.
Ongoing: Competition from established diagnostic companies with greater resources and market share.
Potential: Technological advancements rendering existing tests obsolete.
Ongoing: Regulatory challenges and compliance requirements in the healthcare industry.
Potential: Limited financial disclosure and liquidity due to trading on the OTC Other market.

IDXG的核心优势是什么？

Proprietary PathFinderTG platform.
Specialized focus on pancreatic and thyroid cancer diagnostics.
Established relationships with key physicians and hospitals.
Strong gross margin of 64.6%.

IDXG的劣势是什么？

Small market capitalization of $0.01B.
Limited geographic reach (primarily United States).
Dependence on reimbursement policies for revenue.
Competition from larger diagnostic companies.

IDXG有哪些机遇？

Expansion of PancraGEN and ThyGeNEXT testing services.
Development of new diagnostic assays for other types of cancer.
Strategic partnerships with hospitals and clinics.
Geographic expansion into international markets.

IDXG面临哪些威胁？

Changes in reimbursement policies.
Competition from established diagnostic companies.
Technological advancements rendering existing tests obsolete.
Regulatory challenges and compliance requirements.

IDXG的竞争对手是谁？

AvanCell Therapeutics Inc — Focuses on cell-based therapies. — (AVCRF)
Creative Medical Technology Holdings Inc — Develops regenerative medicine therapies. — (CPIVF)
IC Biomedical — Provides cryogenic storage solutions. — (ICBU)
LIFD Inc — Offers telehealth and remote patient monitoring services. — (LIFD)
RMSL Corp — Provides medical billing and coding services. — (RMSL)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Thomas W. Burnell
Headquarters: Parsippany, US
Employees: 111
Founded: 1998

AI Insight

AI analysis pending for IDXG

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Interpace Biosciences, Inc. do?

Interpace Biosciences, Inc. is a molecular diagnostics company that provides tests and services for assessing cancer risk. They offer a range of diagnostic solutions, including PancraGEN for pancreatic cysts, ThyGeNEXT for thyroid nodules, and RespriDx for lung cancer. Their business model revolves around selling these tests to physicians, hospitals, and clinics, and generating revenue through insurance reimbursement and direct sales. The company leverages its proprietary PathFinderTG platform to develop and commercialize new diagnostic assays, positioning itself as a key player in the personalized medicine space.

What do analysts say about IDXG stock?

As of March 17, 2026, a comprehensive analyst consensus for IDXG is not readily available due to its OTC listing and smaller market capitalization. However, key valuation metrics such as the P/E ratio of 1.56 and gross margin of 64.6% suggest potential value. Growth considerations include the company's ability to expand its test menu, secure favorable reimbursement policies, and penetrate new markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for IDXG?

The main risks for Interpace Biosciences, Inc. include changes in reimbursement policies, competition from larger diagnostic companies, technological advancements rendering existing tests obsolete, and regulatory challenges in the healthcare industry. As an OTC-listed company, IDXG also faces risks related to limited financial disclosure, lower trading volume, and potential price volatility. Investors should carefully assess these risks before investing in IDXG.